Navigation Links
Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
Date:2/25/2009

- New Progression-Free Survival Data Support Picoplatin in Combination with Docetaxel/Prednisone as First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer -

- Results To Be Presented at the American Society of Clinical Oncology's 2009 Genitourinary Cancers Symposium -

SOUTH SAN FRANCISCO, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of new efficacy and safety data from its ongoing Phase 2 clinical trial of picoplatin in combination with docetaxel and prednisone as first-line therapy for metastatic castration-resistant prostate cancer (CRPC). Results showed that the combination is active as first-line therapy for metastatic CRPC (also known as hormone-refractory prostate cancer) as demonstrated by prostate specific antigen (PSA) levels, time to PSA progression and radiologic response rates. Results also continue to show that picoplatin can be safely administered with full-doses of docetaxel and prednisone, the standard treatment for CRPC.

"The time to PSA progression data along with high rates of PSA response in this ongoing Phase 2 trial are encouraging and suggest potential clinical benefit when picoplatin is combined with docetaxel and prednisone as a first-line therapy for patients with CRPC," said William K. Oh, M.D., clinical director of the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute and associate professor, Harvard Medical School. "While awaiting final data from this trial, I believe that the updated results reported to date warrant consideration of a Phase 3 clinical trial to compare picoplatin with docetaxel and prednisone to docetaxel and prednisone alone in metastatic CRPC patients, a group of men with
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
2. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
4. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
5. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
7. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
8. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... “Preparative & Process Chromatography Market by Instrument ... Buffers, Valves, Guages, Seals), Accessories, Services, End User ... 2019” provides a detailed overview of the major ... strategies impacting the preparative and process chromatography market ... revenue and share analysis. , Full Copy ...
(Date:12/24/2014)... Long Island, New York (PRWEB) December 23, 2014 ... , and the Long Island Affiliate of ITRA Global, the ... economy’s slow but steady recovery. This is evidenced by ... and the strong stock market. Low energy costs have ... low. The only negative is the housing market remaining ...
(Date:12/24/2014)... -- China Biologic Products, Inc. (NASDAQ: CBPO, "China ... plasma-based biopharmaceutical company in China ... Taibang Biological Products Co. Ltd., has received Good ... and Drug Administration (the "CFDA") for its new ... the Company,s public filings, the CFDA inspected this ...
(Date:12/24/2014)... YORK , Dec. 23, 2014  NeuroLifeSciences announced ... mazindol in children with attention deficit/hyperactivity disorder published in ... . The paper, titled "Pilot Phase ... disorder" ( Konofal et al, Drug Des ... ) shows that mazindol might be an effective, ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3
... 26 Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) today ... at the Piper Jaffray 19th Annual,Health Care Conference at ... November 28, 2007 at 8:30 a.m. Eastern Time., ... on Lexicon,s,corporate website at http://www.lexpharma.com . An archived ...
... Income up $1,036,024, or 89%, for the nine months ended September 30, ... ... China, Nov. 26 /Xinhua-PRNewswire-FirstCall/ -- China Kangtai,Cactus Bio-tech Inc. (OTC Bulletin Board: ... cactus-based,consumer products, filed its quarterly report on SEC Form 10QSB on November,19, ...
... 26 PRA International,(Nasdaq: PRAI ), a ... Chambers has been named its senior vice president ... to human resources that will,help PRA grow," said ... and employment law in addition to strong tactical ...
Cached Biology Technology:Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference 2China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results 2China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results 3China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results 4Chambers Joins PRA International as Senior Vice President of Human Resources 2
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... Disorders and Stroke (NINDS), a component of the National Institutes ... the Morris K. Udall Centers of Excellence in Parkinson,s Disease ... totaling more than $16 million for Emory University in Atlanta ... NINDS Director Story Landis, Ph.D., announced the ...
... the future" story, scientists today reported that the sustainable, ... ago is re-emerging as a "green" alternative to wood ... the American Chemical Society, they described development of new ... and tofu and could mean a new generation of ...
... increase of up to 4.2 C and the end ... targets are not revised in the Copenhagen Accord, the international ... change conference. Just ahead of the next ... in Tianjin, China, a new report published today, Wednesday, 29 ...
Cached Biology News:NINDS awards new Udall Centers for Parkinson's Disease Research 2NINDS awards new Udall Centers for Parkinson's Disease Research 3Climate accord loopholes could spell 4.2-degree rise in temperature and end of coral reefs by 2100 2
... This kit #27295 has improved stability and convenience ... kit not only has overcome this problem but ... we have changed the formulation of HRP conjugated ... 1). By this change, the stability of the ...
Mouse monoclonal [BC-4] to Aggrecan xxPEN ( Abpromise for all tested applications). entrezGeneID: 176 SwissProtID: P16112...
... screening, low melting point agarose where separation ... recommended for separation of nucleic acids less ... products. Micro ABgarose is also suited to ... blotting techniques. At a 3% concentration, Micro ...
Rabbit polyclonal to Nck alpha ( Abpromise for all tested applications). entrezGeneID: 4690 SwissProtID: P16333...
Biology Products: